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a b s t r a c t
The incidence of human papillomavirus (HPV)-associated epithelial lesions is substantially higher in
human immunodeﬁciency virus (HIV)-infected individuals than in HIV-uninfected individuals.
The molecular mechanisms underlying the increased risk of HPV infection in HIV-infected individuals
are poorly understood. We found that HIV proteins tat and gp120 were expressed within the oral and
anal mucosal epithelial microenvironment of HIV-infected individuals. Expression of HIV proteins in the
mucosal epithelium was correlated with the disruption of epithelial tight junctions (TJ). Treatment of
polarized oral, cervical and anal epithelial cells, and oral tissue explants with tat and gp120 led to
disruption of epithelial TJ and increased HPV pseudovirion (PsV) paracellular penetration in to the
epithelium. PsV entry was observed in the basal/parabasal cells, the cells in which the HPV life cycle is
initiated. Our data suggest that HIV-associated TJ disruption of mucosal epithelia may potentiate HPV
infection and subsequent development of HPV-associated neoplasia.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus (HPV) is the causative agent of cervical
and anal cancers, and a subset of oral and other epithelial cancers
(Palefsky, 2006). The prevalence and incidence of anogenital HPV
infection in HIV-infected individuals are substantially higher than
in HIV-uninfected individuals (Palefsky et al., 1998). HIV-infected
individuals also have an increased risk of HPV-associated neo-
plasia (Palefsky, 2009, 2012). Once HPV infection is established,
attenuated immunity may reduce viral clearance and ultimately
contribute to development of HPV-associated neoplasia. However,
direct and indirect interactions between HIV and HPV within the
epithelium may also play a role in the ﬁrst step of the process, i.e.,
initial HPV infection of the epithelium.
In contrast to other HIV-associated malignancies, the incidence
of HPV-associated cancers such as anal cancer has increased, not
decreased since the introduction of antiretroviral therapy (ART)
(Palefsky, 2009). Several studies have shown that ART for HIV
infection has done little to reduce the increased risk of anal HPV
infection in men and women (Palefsky et al., 2005; Hessol et al.,
2009). Others have shown a beneﬁt for clearance of cervical HPV
infection in HIV-infected women and anal HPV infection in men
upon initiation of ART but overall the prevalence of both cervical
and anal HPV infection remains high among HIV-infected indivi-
duals in the ART era (de Pokomandy et al., 2009). The mechanisms
underlying the limited beneﬁt of ART with respect to the continued
high prevalence and incidence of HPV infection in HIV-infected
individuals are poorly understood (Kang and Cu-Uvin, 2012).
Development of HPV-associated neoplasia is initiated upon
HPV entry into basal and parabasal cells of the epithelium. Animal
model work suggests that HPV penetration through multiple
layers of the stratiﬁed squamous epithelium requires a mechanical
breach or tear (Roberts et al., 2007). It is possible that co-infection
with viruses such as HIV may also lead to epithelial disruption. If
so, HIV-associated epithelial disruption may be one mechanism
contributing to the increased risk of HPV infection among HIV-
infected individuals. Several studies have shown that HIV infection
can disrupt intestinal mucosal epithelium (Kapembwa et al., 1991,
1996; Maingat et al., 2011; Obinna et al., 1995; Sankaran et al.,
2008). However, HPV is not known to infect the intestinal
epithelium, and the effect of HIV infection on the integrity of oral
and anogenital mucosal epithelia, which are both targets for HPV
infection, has not been well investigated.
Tat and gp120 are HIV proteins that are secreted from HIV-
infected intraepithelial immune cells. These proteins may play an
important role in disruption of epithelial tight junctions (TJ) and
HPV entry into epithelium. Tat is a transactivator protein that
activates integrin and mitogen-activated protein kinases (MAPK)
signaling, which in turn may disrupt endothelial and epithelial cell
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junctions through aberrant internalization of TJ proteins (Andras
et al., 2005; Bai et al., 2008; Pu et al., 2005; Song et al., 2007; Toschi
et al., 2006; Zhong et al., 2008). HIV gp120 is an envelope protein
that binds to galactosyl ceramide of epithelial cells, induces intra-
cellular calcium elevation (Bozou et al., 1989; Dayanithi et al., 1995;
Fantini et al., 2000) and activates protein kinase C (PKC). PKC
activates p38 mitogen-activated protein kinases, phosphoinositide
3 kinases/protein kinase B (PI3K/AKT), and c-Jun N-terminal kinases
(JNK) (Ali et al., 2009; Cai et al., 1997; Kawakami et al., 2004; Lopez-
Bergami et al., 2005; Marshall, 1996; Preiss et al., 2007; Wang et al.,
2004; Zhou et al., 2003). This leads to the disruption of epithelial TJ
(Gonzalez-Mariscal et al., 2008; Kanmogne et al., 2005, 2007; Kevil
et al., 2000, 2001; Wang et al., 2004; Yang et al., 2009) through
modulation of TJ protein internalization and/or TJ gene expression
(Alcorn et al., 2008; Shintani et al., 2006). HIV gp120 also disrupts
TJs (Kanmogne et al., 2005, 2007) through induction of proteasome-
mediated degradation of ZO-1 and ZO-2 (Nakamuta et al., 2008)
and internalization of occludin and claudins (Shen and Turner,
2005; Shin et al., 2006; Umeda et al., 2006).
If HIV infection is indeed a biologically relevant contributor to
mucosal epithelium disruption and entry of HPV into epithelium,
then HIV proteins should be present in the mucosal environment,
even among HIV-infected individuals with well-controlled HIV
viral load on ART. Cell-free HIV-1 virions and viral DNA/RNA can be
isolated from oral and genital mucosal epithelium, as well as the
saliva and cervicovaginal secretions of HIV-infected individuals
(Chou et al., 2000; Clemetson et al., 1993; Crowe and Sonza, 2000;
Goto et al., 1991; Henning et al., 2010; Kakizawa et al., 1996; Liuzzi
et al., 1996; Maticic et al., 2000; Nuovo et al., 1993; Qureshi et al.,
1997, 1995; Rodriguez-Inigo et al., 2005; Sonza et al., 2001;
Zuckerman et al., 2003). HIV-infected lymphocytes, and Langer-
hans cells can be detected in the mucosal and submucosal layers of
oral and genital epithelium (Chou et al., 2000; Jayakumar et al.,
2005; Qureshi et al., 1995, 1997; Rodriguez-Inigo et al., 2005), and
HIV virions can be detected by electron microscopy, within the TJs
of oral epithelium (Qureshi et al., 1997). Finally, replicating HIV
and HIV-infected cells have been found within cervical epithelia of
HIV-infected women, including women on ART (Crowe and Sonza,
2000; Henning et al., 2010; Sonza et al., 2001).
To model the role of tat and gp120 on mucosal epithelial TJ
integrity and penetration of HPV into epithelium, we used HPV 16
pseudovirions (PsV) containing a plasmid expressing red ﬂuorescent
protein (RFP) (Buck et al., 2006; Roberts et al., 2007). We used
polarized oral, anal and cervical epithelial cells to model passage of
PsV through a single layer of squamous epithelial cells with intact TJ,
as might be found in the stratum granulosum or spinosum of a multi-
stratiﬁed epithelium. We also used oral mucosal epithelial tissue
explants to model the effect of HIV proteins through intact, multi-
stratiﬁed squamous epithelium. Our data show that HIV tat and gp120
disrupt TJ in mono-stratiﬁed and multi-stratiﬁed mucosal epithelium,
facilitating PsV paracellular penetration between cells with TJs. Para-
cellular penetration of HPV-16 PsV in oral mucosal tissues through
superﬁcial cell layers with disrupted TJ led to entry of PsV into basal
and parabasal cells, the site of initiation of the HPV lifecycle. Together
our data indicate that HIV tat and gp120 proteins may disrupt mucosal
epithelial TJ and potentiate development of HPV-associated neoplasia
by facilitating HPV entry into mucosal epithelium.
Results
Disruption of tight junctions (TJ) in vivo in oral and anal mucosal
epithelia of HIV-infected individuals
To determine whether mucosal epithelium TJ disruption occurs
in vivo naturally in the setting of HIV infection, cryosections of
clinically and histologically normal oral biopsies from 12 HIV-
infected and 4 HIV-uninfected individuals were immunostained
for TJ markers: zonula occludens (ZO-1), occludin and claudin-1. Six
of the 12 HIV-infected donors (50%) were on antiretroviral therapy
(ART). Expression and localization of ZO-1 (Fig. 1), occludin and
claudin-1 (data not shown) in tissues of all four HIV-uninfected
donors were strong and in a ring shape (Fig. 1A, upper left panel),
indicating the presence of intact TJs. However, in oral tissues from
8 of 12 (67%) HIV-positive donors including three donors on ART,
these proteins were found in a diffuse, dot-like pattern in the
cytoplasm, indicating TJ disruption (Fig. 1A, upper middle panel).
Quantitation of cells with a normal pattern of ZO-1, occludin and
claudin-1 within the oral epithelium from ART-treated HIV-infected
individuals showed that the number of cells with a normal pattern
Fig. 1. Disruption of TJs of HIV-infected oral and anal mucosal epithelia. (A) Oral
and anal biopsies from HIV-infected and HIV-uninfected individuals were immu-
nostained for ZO-1 (red). As a negative control, sections were stained with rabbit
IgG. GR, granulosum; SP, spinosum; BL, basal; LP, lamina propria. Nuclei are stained
in blue. Original magniﬁcation was 400. Representative immunoﬂuorescence
images are shown. (B) For quantitative evaluation of TJ protein expression in oral
and anal tissues of HIV-infected and HIV-uninfected individuals, epithelial cells
expressing ZO-1, occludin, and claudin-1 in ring-shaped patterns were counted
from 10 randomly selected regions of mucosal epithelia. Cells were counted in
10 ﬁelds of each tissue section. Results were obtained from oral biopsies (four
HIV-uninfected, six HIV-infected on ART and six HIV-infected not on ART) and anal
biopsies (ﬁve HIV-negative, six HIV-infected on ART and three HIV-infected not on
ART). Results are represented as a percentage of epithelial cells with a normal
pattern (ring shape) of ZO-1, occludin and claudin-1 expression. Error bars
represent standard errors of the means. *Po0.05, **Po0.01, ***Po0.001, all
compared with the HIV-uninfected control group.
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was reduced by approximately 25–30% compared with HIV-
uninfected donors (ZO-1 p¼0.03, occludin p¼0.02 and claudin
p¼0.01). Analysis of TJ disruption in HIV-infected donors not on
ART showed that all had substantial disruption of TJs, i.e., the
number of epithelial cells with a normal pattern of ZO-1, occludin
and claudin-1 was reduced by approximately 65–70% compared
with the epithelia of HIV-uninfected individuals (ZO-1, occludin and
claudin-1 po0.001).
Similar observations of TJ disruption were found in the anal
epithelium of HIV-infected individuals. We examined the status of
TJs in normal anal biopsies from ﬁve HIV-uninfected donors, and
normal anal biopsies from nine HIV-infected individuals, six of
whomwere on ART. Each of the histologically normal anal biopsies
from the ﬁve HIV-uninfected individuals showed intact TJs
(Fig. 1A, lower panel), whereas all the histologically normal anal
biopsies from HIV-infected individuals had disrupted TJs. The anal
epithelium of HIV-infected patients on ART contained 20–30%
fewer cells with a normal pattern of ZO-1, occludin and claudin-1
(ZO-1 p¼0.03, occludin p¼0.01, claudin-1, p¼0.03) compared
with biopsies from HIV-uninfected donors. Biopsies from each of
the six HIV-infected individuals not on ART showed even more
pronounced TJ disruption. Compared with HIV-uninfected donors,
approximately 70% of anal epithelial cells in HIV-infected indivi-
duals lost a normal ring pattern of ZO-1, occludin and claudin-1
(ZO-1, occludin, claudin-1, po0.001). These data indicate that HIV
infection was accompanied by disruption of TJs within normal oral
and anal epithelia, even among those on ART. However, junctional
disruption at both mucosal sites was most pronounced among
HIV-infected individuals not on ART.
HIV-tat and gp120 disrupt TJ of polarized epithelial cells
HIV proteins tat and gp120 have been shown to disrupt endo-
thelial, retinal, intestinal and endometrial epithelial TJs (Andras et al.,
2005; Bai et al., 2008; Nakamuta et al., 2008; Nazli et al., 2010; Pu
et al., 2005; Song et al., 2007; Zhong et al., 2008). To determine if
these proteins are playing a role in disrupting epithelial TJ as seen in
oral and anal biopsies, we used mono-stratiﬁed-polarized oral
(Fig. 2), anal and cervical (data not shown) epithelial cells with intact
TJ. Previous in vitro studies of the effect of HIV proteins on TJ function
used concentrations of tat (1 mg/ml and higher) and gp120
(100 ng/ml) (Andras et al., 2005; Bai et al., 2008; Nazli et al., 2010;
Pu et al., 2005; Song et al., 2007; Toschi et al., 2006; Zhong et al.,
2008) that were substantially higher than physiological concentra-
tions. Serum HIV-tat and gp120 levels may reach up to 40 ng/ml and
15 ng/ml in HIV-infected individuals, respectively (Poggi and Zocchi,
2006; Rychert et al., 2010; Westendorp et al., 1995; Xiao et al., 2000).
Therefore, in our experiments we used concentrations of tat
and gp120 at 10 ng/ml of each, similar to physiological levels in
HIV-infected individuals.
Oral, cervical and anal cells were grown until they polarized
sufﬁciently to form fully functional TJ as indicated by trans-
epithelial resistance (TER). We added recombinant tat and gp120
separately and together to the polarized cells for 5 days and
monitored TER (Fig. 2A). As a negative control we used mutant tat
protein (HIV-1BAL strain) that lacks the basic and integrin-binding
domains, and is not internalized into cells (Barillari et al., 1999a,
1999b; Nagahara et al., 1998; Toschi et al., 2006). Heat-inactivated
gp120 (HIV-1BAL strain) was used as a negative control for gp120
experiments. We added recombinant tat and gp120 to the apical
surface of polarized cells. Culture media were changed daily with
fresh proteins. Consistent with the disruption of TJs, TER gradually
declined in polarized cells treated with tat and gp120 (Fig. 2A)
independently and synergistically. In contrast, the TER of polarized
cells increased over a 5-day period when untreated or treated with
the inactive tat and heat-inactivated gp120 proteins. Tat- and
gp120-induced TER reduction was detected only with prolonged
exposure to active proteins (4–5 days); shorter treatment (1–3
days) did not lead to TER reduction.
As an additional measure of TJ functional integrity, we also
examined paracellular permeability of polarized oral epithelial
cells to horseradish peroxidase-conjugated goat anti-donkey IgG
(Tugizov et al., 2011). At 5 days IgG was added to the apical surface
and measured in the lower chamber media. Paracellular leakage of
IgG was detected only in those cells treated with active tat and/or
gp120 (Fig. 2B, upper panel). IgG leakage was not detected in
untreated cells, or cells treated with the inactive tat and/or heat-
inactivated gp120 proteins. Treatment with tat and/or gp120
proteins was not toxic to the polarized cells (Fig. 2B, lower panel).
Polarized cells treated with active tat and gp120 showed complete
TJ disruption on confocal microscopy after 5 days (Fig. 2C) in
contrast to untreated cells and cells treated with inactive tat and
gp120, which showed intact TJ. Four independent experiments
with polarized oral epithelial cells showed similar data. HIV tat-
and/or gp120- mediated disruption of TJs was also detected using
paracellular IgG leakage in polarized anal and cervical epithelial
cells (data not shown).
Fig. 2. Role of HIV proteins tat and gp120 in the disruption of oral epithelial tight
junctions. (A) Polarized oral epithelial cells were treated with an active and inactive
recombinant HIV tat or gp120, separately or in combination. TER was measured daily.
(B) (upper panel) The same cells were used to measure paracellular permeability
after 5 days of treatment. IgG leakage into lower chambers is presented as a % of
apical value of tracer. (Lower panel) After measuring paracellular permeability, cells
were examined for viability using an MTT assay. RLU, relative luminescence units.
(C) At 5 days, untreated control cells and cells treated with inactive and active tat and
gp120 were immunostained for occludin (green). Cell nuclei are stained in blue.
(A and B) Error bars show7s.e.m. (n¼3).
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HIV tat- and gp120-associated TJ disruption of polarized monolayer
epithelial cells facilitates paracellular passage of HPV PsV
To determine whether tat/gp120-mediated TJ disruption pro-
motes paracellular passage of HPV through polarized oral epithe-
lial cells, the cells were treated with a combination of tat and
gp120 for 5 days, and when TER values were reduced by 90% we
exposed the apical surfaces to HPV-16 PsVs. To examine para-
cellular passage of PsV via disrupted polarized cells, COS-1 cells
were grown in the lower chamber of 12 well plates where
transwell inserts were placed (Fig. 3A).
Paracellular PsV passage was examined by detection of RFP
ﬂuorescence in COS-1 cells (Fig. 6A, and B upper panel). Although
COS-1 cells are not normal host cell types for authentic HPV
infection they were used for the evaluation of HPV PsV paracel-
lular passage via TJ-disrupted epithelial cells because they are
highly sensitive for measurement of HPV-16 PsV entry and detec-
tion of RFP expression. Quantitative analysis of RFP-positive COS-1
cells showed that polarized oral epithelial cells treated with
tat/gp120 had PsV paracellular passage leading to infection of
approximately 40% of the COS-1 cells. In contrast, no RFP-positive
COS-1 cells were detected after PsV were added to control cells
with intact TJs (Fig. 3B, lower panel). Similar data were obtained
with polarized anal and cervical epithelial cells (data not shown).
HIV tat- and gp120-mediated TJ disruption potentiates PsV
penetration into oral multi-stratiﬁed epithelium
Having shown that HIV tat and gp120 disrupt TJs in mono-
stratiﬁed polarized oral, anal, and cervical epithelial cells and
facilitate paracellular passage of HPV-16 PsV between the cells, we
next sought to determine whether these proteins were playing a
role in PsV entry into multi-stratiﬁed mucosal epithelium. For
these experiments we used buccal explants from HIV-uninfected
donors. We exposed buccal explants from 12 different HIV-
uninfected donors to HIV tat at 30 ng/ml for 2 days. Matching
buccal explants were maintained without tat and served as
controls. The tissue explants were then exposed to HPV-16 PsVs
for 3 days. Culture media were replaced every day with media
containing fresh tat. Tat was therefore present in the apical media
during the entire 5-day experimental period. After 5 days, the
tissues were ﬁxed, sectioned and analyzed for ZO-1 and PsV-RFP
expression. Confocal microscopy showed a diffuse cytoplasmic ZO-
1 pattern in the tat-treated epithelia of seven of the 12 (58%)
explants (Fig. 4A, right panel). All matching explants not treated
with tat exhibited normal ring-shaped ZO-1 localization within
the lateral membranes, indicating intact TJ. In three of the seven
tat-disrupted explants (42%), PsV-RFP expression was detected
within the basal and parabasal layers of epithelium (Fig. 4A).
Quantitative analysis showed that approximately 5–8% of basal/
parabasal cells were positive for PsV-RFP (Fig. 4B). PsV penetration
was not detected in four of the tat-disrupted tissues. No PsV entry
was detected in any of the ﬁve tissues treated with tat but
which retained normal ZO-1 localization, or in control explants
not treated with tat.
We next exposed buccal explants from ﬁve different HIV-
uninfected donors to a combination of tat and gp120 (30 ng/ml
of each), and PsV penetration was examined as described above.
After 5 days tissues were analyzed by confocal microscopy, which
revealed a diffuse cytoplasmic ZO-1 pattern in the tat/gp120-
treated epithelium of three of the ﬁve explants (Fig. 4C). In these
disrupted tissues, PsV-RFP expression was detected within the
basal and parabasal layers of epithelium. Approximately 15% of
parabasal cells expressed PsV-RFP (Fig. 4D). No PsV entry was
detected in the three explants treated with tat and gp120 but
which retained normal ZO-1 localization, or in control tissues not
treated with tat and gp120.
Expression of HIV tat and gp120 in oral and anal epithelial tissues of
HIV-infected individuals
Above we showed that oral and anal epithelial TJs are disrupted
in normal tissues in HIV-infected individuals in vivo, and that
disruption of TJs by HIV tat and gp120 potentiates PsV entry when
added exogenously to multi-stratiﬁed epithelium. We then sought
to determine if these proteins can be detected in vivo in oral and
anal biopsies, and whether their expression is associated with TJ
Fig. 3. Role of tat- and gp120- disrupted epithelial TJ in paracellular spread HPV-16
PsVs. (A) Model of HPV-16 PsV paracellular passage between disrupted mucosal
epithelia. Polarized cells were grown in the upper chambers of two-chamber
transwell ﬁlter inserts. COS-1 cells were grown in the lower chambers of the ﬁlter
inserts, in the well where the ﬁlter inserts were then placed. To examine
paracellular passage of HPV-16 PsVs, PsVs were added to the apical surfaces of
polarized epithelial cells. At 2 h post-inoculation, ﬁlter inserts were removed, and
the extent of paracellular passage of PsVs was determined in the COS-1 cells by
detecting RFP ﬂuorescence. (B, upper panel) Polarized oral epithelial cells were
incubated for 5 days with HIV-tat and gp120 or their inactive forms. HPV-16 PsVs
were then added to the apical surfaces and paracellular passage of HPV-16 PsVs
across disrupted oral epithelium was examined by detection of RFP-positive COS-1
cells. (B, lower panel) Paracellular passage of HPV-16 PsVs across disrupted oral
epithelium was quantitated by counting RFP-positive COS-1 cells. Results are
presented as a % of RFP-positive cells. Error bars show7s.e.m. (n¼3). *, not
detected.
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disruption. In Fig. 1 we showed that the TJs were disrupted in the
oral and anal tissues from HIV-infected individuals. Here, we
examined the presence of HIV tat- and gp120-expressing macro-
phages, T lymphocytes and Langerhans cells (LCs) in similar oral
and anal biopsy samples. Confocal immunoﬂuorescence micro-
scopy of 12 oral and nine anal biopsies from HIV-infected donors
showed HIV-tat-positive and gp120-positive intraepithelial and
submucosal macrophages (Fig. 5A), T lymphocytes and LCs (data
not shown) in all biopsies, including all the donors on ART. Tat and
gp120-expressing intraepithelial immune cells were detected in
tissues from donors with a wide range of HIV plasma viral load,
including four of the 21 donors with an undetectable plasma viral
load. Cells expressing tat and gp120 were not detected in any of the
four oral and ﬁve anal biopsies from HIV-uninfected individuals.
Quantitative analysis of HIV tat- and gp120-expressing cells in
anal and oral biopsies from HIV-infected individuals on ART and
not on ART showed that tissues from individuals not on ART
contained a higher number of macrophages and T lymphocytes
expressing tat and gp120 than tissues from ART-treated indivi-
duals (po0.05; Fig. 5B). The numbers of LCs in oral and anal
tissues from donors on or not on ART were not signiﬁcantly different.
Mucosal epithelium of HIV-infected individuals contains
infectious HIV
HIV virions could be a possible direct source of secreted tat and
gp-120 within tissues. To determine if tat- and gp120-positive
immune cells within the mucosal epithelium also contain intact,
infectious HIV virions, we looked for the presence of infectious HIV
in tissues shown to contain gp120 and tat. Protein was extracted
from 14 anal biopsies from HIV-infected individuals on ART and
ﬁve anal biopsies from HIV-uninfected donors, and examined for
HIV p24 using an ELISA assay. Our data showed that 11 of the 14
anal biopsies from HIV-infected donors contained HIV-1 p24
(Fig. 6A, upper panel), indicating that virions were present within
the mucosal environment. HIV p24 was not detected in the tissues
obtained from HIV-uninfected donors (data not shown). We then
infected peripheral blood mononuclear cell (PBMC) with extracts
of the HIV-infected anal biopsies. At 2 weeks post-infection p24
ELISA assays showed that virions from 2 of 11 (18%) HIV-infected
biopsies were infectious in PBMCs (Fig. 6A, lower panel). These
data show that the anal mucosal epithelium and/or submucosal
lamina propria of at least some HIV-infected individuals on ART
contain infectious virus.
HIV tat and gp120 are detectable in saliva and HIV tat can penetrate
into stratiﬁed mucosal epithelium
Above we showed that the oral and anal mucosal epithelium
contain HIV that could shed tat and gp120 proteins within the
epithelial environment. Since saliva may represent another poten-
tial source of tat and gp120 for the epithelium we analyzed nine
whole saliva and matching plasma samples from HIV-infected
individuals not on ART to determine if these proteins are detect-
able in saliva. Using a combination of immunoprecipitation and
Western blotting, we showed that three of the nine (33%) saliva
samples were positive for gp120 or tat (Fig. 6B). Two saliva
samples positive for gp120 were also positive for tat.
To determine if salivary tat at physiologic concentrations could
penetrate into mucosal epithelium we exposed the normal
Fig. 4. HIV-associated disruption of mucosal epithelium facilitates PsV entry into basal and parabasal cells. (A and B) Buccal explants were treated with HIV tat alone (A) or
HIV tat and gp120 in combination (B) for 2 days and then exposed to HPV-16 PsVs for the next 3 days. Tissues were immunostained for ZO-1 (red) and analyzed for PsV-RFP
by confocal microscopy. GR, granulosum; SP, spinosum; BL, basal; LP, lamina propria. (C and D) PsV penetration of HIV tat- and gp120-treated explants was quantiﬁed by
counting RFP-positive epithelial cells; data are presented as the percentage of cells positive for PsV-RFP. Error bars show7s.e.m. (n¼10). *, not detected.
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mucosal surface of polarized buccal tissue explants from HIV-
uninfected donors to 30 ng/ml GFP-labeled HIV-tat in saliva. After
1 h and 3 h, the tissues were analyzed by confocal microscopy, and
showed that tat-GFP from saliva penetrated the mucosal epithe-
lium from the apical surface to granulosum and spinosum layers in
a time-dependent manner (Fig. 6C).
Discussion
The granulosum and spinosum layers of oral and anal mucosal
epithelium have well-developed TJs that form a barrier in the
upper part of the stratiﬁed epithelium (Tugizov et al., 2012). The
role of this barrier in preventing HPV from reaching the HPV-
susceptible basal and parabasal cell layers during initial infection
is poorly understood. Here we show that TJ disruption oral and
anal epithelium in HIV-infected individuals due to expression of
the HIV tat and gp120 serves as a mechanism for potentiating HPV
penetration into epithelium. In turn this may contribute to the
higher prevalence of anogenital and oral HPV infection, and
ultimately, increased risk of HPV-associated neoplasia in these
individuals.
HPV-16 PsVs readily penetrated into HIV tat- and gp120-
disrupted oral epithelium as far down as the basal/parabasal layer,
whereas no penetration was seen in intact tissues not treated with
these proteins. We observed that all tat/gp120-disrupted epithelia
facilitate PsV penetration; however, approximately half of tat-
disrupted tissues did not allow PsV penetration. Lack of PsV
penetration in some of the disrupted epithelia could be due to
clearance or damage of PsVs by intraepithelial macrophages
and/or innate immune molecules, respectively (Buck et al., 2006;
Ishii, 2013). Efﬁcient paracellular passage of HPV-16 PsVs through
HIV tat/gp120-disrupted TJs of mono-stratiﬁed epithelial cells is
consistent with our demonstration that PsV migration into basal/
parabasal cells of stratiﬁed mucosal epithelium occurred by TJ
disruption in the granulosum and spinosum layers. The detection
of RFP expression predominately in parabasal cells suggested
that initial PsV entry may occur in basal cells, which may later
become stratiﬁed into parabasal layers. Epithelial lesions arise
when basal/parabasal cells infected with HPV rise through the
epithelium, following a well-described sequence of coordinated
viral transcription and host cell differentiation.
The presence of HIV and HIV gene products are well described
in epithelium (Chou et al., 2000; Clemetson et al., 1993; Crowe and
Sonza, 2000; Goto et al., 1991; Henning et al., 2010; Kakizawa
et al., 1996; Liuzzi et al., 1996; Maticic et al., 2000; Nuovo et al.,
1993; Qureshi et al., 1995, 1997; Rodriguez-Inigo et al., 2005;
Sonza et al., 2001; Zuckerman et al., 2003), largely in circulating
HIV-infected immune cells (Crowe and Sonza, 2000; Henning
et al., 2010; Sonza et al., 2001). We detected immune cells
expressing tat and gp120 in the oral and anal mucosa of all HIV-
infected individuals, including those on ART. Similarly we showed
that HIV in anal tissues was replicating and infectious, including
tissues from ART-treated donors. Furthermore, tat and gp120 were
detected in the saliva, and salivary tat penetrated into mucosal
epithelium. HIV tat may penetrate into cells and tissues through its
protein transduction domain (PTD), based on the basic amino acids
arginine and lysine, which facilitates protein internalization into
cells and tissues by multiple mechanisms, including endocytosis
and macropinocytosis (Ferrari et al., 2003; Fittipaldi et al., 2003;
Kaplan et al., 2005; Mann and Frankel, 1991; Wadia et al., 2004).
Mucosal epithelium may therefore be exposed to tat and gp120
from multiple sources, including saliva and circulating immune
cells, even among individuals with HIV viral load suppression on
ART. Mucosal epithelium also serve as a viral reservoir (Henning
et al., 2010), and a source of proteins that reduce epithelial
integrity in the setting of HIV infection.
Detection of tat and gp120 in oral and anal tissues from HIV-
infected donors on ART is consistent with previous studies, in
which HIV RNA, DNA and virions in the oral and cervical tissues
have been demonstrated (Chou et al., 2000; Clemetson et al., 1993;
Crowe and Sonza, 2000; Goto et al., 1991; Henning et al., 2010;
Kakizawa et al., 1996; Liuzzi et al., 1996; Maticic et al., 2000; Nuovo
et al., 1993; Qureshi et al., 1995, 1997; Rodriguez-Inigo et al., 2005;
Sonza et al., 2001; Zuckerman et al., 2003). Secretion of HIV tat
into blood was ﬁrst shown by Westendorp et al. (1995) and the
ﬁnding was conﬁrmed by others (Poggi and Zocchi, 2006; Xiao
et al., 2000). Detection of gp120 in the blood and lymphoid tissues
Fig. 5. Distribution of HIV-tat- and gp120- expressing immune cells in oral and anal epithelia of HIV-infected individuals. (A) Oral and anal tissue sections from HIV-
uninfected and -infected individuals were co-immunostained for HIV-tat or gp120 (both in green) and CD68 (in red), a marker for macrophages. Yellow indicates
co-localization of viral proteins with cellular markers. Nuclei are in blue (A–C). EP, epithelium; LP, lamina propria. The dotted white line indicates the boundary between the
epithelium and the lamina propria. Original magniﬁcation was 400. Representative immunoﬂuorescence images are shown. (B) For quantitative evaluation, we counted
CD3-, CD68-, and CD1a-positive cells expressing HIV-tat or gp120 in oral and anal tissue sections obtained from HIV-infected individuals on ART (six oral and six anal
biopsies) and not on ART (six oral and three anal biopsies). Cells expressing HIV tat and gp120 were counted in 10 microscopic ﬁelds, and results are represented as the
average number of cells per mm2. Error bars show the standard error of means. *P40.05, as compared with control group
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was also shown (Montagnier et al., 1985; Oh et al., 1992; Rychert
et al., 2010; Santosuosso et al., 2009). A recent report showed
that ART did not inhibit secretion of tat (Mediouni et al., 2012).
ART also did not eliminate gp120 expression in lymph nodes
(Crowe and Sonza, 2000; Hatano et al., 2010; Henning et al., 2010;
Schupbach et al., 2005; Zhang and Crumpacker, 2001). Low levels
Fig. 6. Mucosal epithelium of HIV-infected individuals contains infectious HIV, which express HIV tat and gp120 proteins with the mucosal environment. (A, upper panel) To
detect HIV in the mucosal epithelium, anal biopsies were homogenized, and supernatants were examined for HIV p24 by ELISA. The p24 value was expressed in ng of p24 per
mg of tissue. (A, lower panel) To examine the infectivity of intra-mucosal HIV, PBMCs were infected with homogenates, and p24 was quantiﬁed after 2 weeks. (B) HIV tat and
gp120 in saliva and plasma samples of HIV-infected patients were detected by immunoprecipitation and Western blot assays. IgG HC, IgG heavy chain. IgG LC, IgG light chain.
(C) Polarized oriented buccal explants were treated with GFP-labeled recombinant tat at 30 ng/explant for 1 and 3 h and sectioned and examined for tat penetration by
confocal microscopy. GR, granulosum; SP, spinosum; BL, basal; LP, lamina propria.
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of replicating HIV and viral p24 were detected in peripheral blood
mononuclear cells of ART-treated patients (Crowe and Sonza,
2000; Hatano et al., 2010; Henning et al., 2010; Schupbach et al.,
2005; Zhang and Crumpacker, 2001), which may migrate into
mucosal epithelium leading to spread of HIV (Crowe and Sonza,
2000; Henning et al., 2010; Sonza et al., 2001).
HIV tat- and/or gp120-mediated TJ disruption was detected only
after prolonged incubation of cells (4–5 days) and this effect was
not observed during shorter incubation periods (1–3 days). Earlier
studies have shown that these proteins may disrupt epithelial TJs
during a shorter time (24 h) incubation (Andras et al., 2005; Bai
et al., 2008; Nazli et al., 2010; Pu et al., 2005; Song et al., 2007;
Toschi et al., 2006; Zhong et al., 2008); however, in those studies,
the concentration of proteins was substantially higher than in our
experiments, which were performed at physiological concentra-
tions. Furthermore, in our studies, the development of TJs in
polarized cells was much stronger (TER reached up to 800 Ω/cm2)
than in the earlier studies (TER was about 200–300 Ω/cm2). These
factors may account for the differences of TJ disruption by HIV
proteins in our work compared with previously published work.
In summary, we have observed HPV entry into disrupted mucosal
epithelium facilitated by HIV tat and gp120 proteins, which may have
a synergistic and/or additive effect on TJ disruption. HIV-associated TJ
disruption is likely to play an important role in increasing the risk of
HPV infection. Combined with other factors such as attenuated
immune response to HPV antigen, this may increase the risk of
subsequent development of HPV-associated neoplasia. Topical inhi-
bitors of HIV tat- and gp120-activated signaling molecules including
MAPK, PI3K/AKT and JNK (Ali et al., 2009; Andras et al., 2005; Bai
et al., 2008; Cai et al., 1997; Kawakami et al., 2004; Lopez-Bergami
et al., 2005; Marshall, 1996; Preiss et al., 2007; Pu et al., 2005; Song
et al., 2007; Toschi et al., 2006; Wang et al., 2004; Zhong et al., 2008;
Zhou et al., 2003) that contribute to TJ disruption in HIV-infected
individuals may be useful for improving mucosal epithelial integrity
and reducing the risk of exposure to HPV and potentially other
infectious agents in the environment.
Materials and methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Committee on Human Research of the University of California San
Francisco (IRB approval #: H8597-30664-03). All subjects provided
written informed consent for the collection of samples and sub-
sequent analysis.
Collection of oral and anal tissues and establishment of polarized
oriented tissue explants
Buccal and anal biopsies containing stratiﬁed squamous mucosal
epithelium and lamina propria from HIV-uninfected and HIV-
infected individuals were collected from the UCSF Oral AIDS Center
and UCSF Anal Neoplasia Clinic. To establish polarized organ cultures,
biopsies were used approximately 1–2 h after biopsy procedures.
Explants were placed with the mucosal side facing up in the top
chamber of Millicell ﬁlter inserts of 12 mm diameter and 0.4-mm
pore size (Millipore). The lateral edges of the explants were sealed
with 3% agarose as described previously (Tugizov et al., 2012).
Establishment of polarized epithelial cells
Primary cervical keratinocytes from ectocervical tissues were
purchased from Lonza. Primary anal and tonsil keratinocytes were
established in our laboratory as described (Tugizov et al., 2011).
Polarized cells were established in 0.4-mm transwell two-chamber
ﬁlter inserts (Tugizov et al., 2003, 2011).
Treatment of polarized cells and tissue explants with HIV proteins
tat and gp120
Recombinant HIV-1 (Bal strain) wt tat and inactive mutant tat
proteins were purchased from Immunodiagnostic Inc. Mutant tat
was generated by substitution of the basic arginine-rich domain at
49–57 aa and the integrin-binding RGD motif in the C terminus
with alanines. HIV-1 (Bal strain) gp120 was provided by the NIH
AIDS Research reagent program. Gp120 was inactivated by incuba-
tion of protein at 85 1C for 30 min (Bai et al., 2008).
To examine penetration of GFP-labeled HIV tat into oral epithe-
lium, polarized oriented adult buccal explants were incubated at
their mucosal surfaces with 30 ng/ml of HIV tat-GFP fusion protein
(pEGFP/HXB-2 kindly provided by Dr. Ashok Chauhan, University of
South Carolina) in the presence of whole saliva for 1 and 3 h at
37 1C. Whole saliva was collected from ﬁve HIV-uninfected healthy
donors and pooled and then used for tat reconstitution.
Recombinant tat and gp120 were added to polarized cells or tissue
explants separately and in combination. Culture media were changed
every day with fresh virus or proteins. In polarized cells disruption of
tight junctions was monitored by measuring transepithelial electrical
resistance (TER) and paracellular permeability (Tugizov et al., 2003,
2011). Brieﬂy, TER was measured with an epithelial Millicell-ERS
voltohmmeter (Millipore). Paracellular permeability was evaluated
by adding horseradish peroxidase-conjugated goat anti-donkey IgG
(Fab)2 (Jackson ImmunoResearch) to the upper ﬁlter compartment
and photometrically assaying the medium from the lower compart-
ment for horseradish peroxidase with o-phenylenediamine dihy-
drochloride as the substrate (Gulino et al., 1998). Detection of IgG in
the lower chamber indicated leakage of IgG from the upper chamber.
MTT assay was used to determine the viability of polarized cells
treated with proteins (Biotium Inc.). Disruption of polarized cells in
the tissue explants was examined by immunostaining of tissue
sections for ZO-1.
Preparation of HPV-16 pseudovirions (PsVs)
HPV-16 pseudovirions (PsV) consist of the major L1 and minor
L2 capsid proteins of the virion, with a plasmid expressing red
ﬂuorescent protein (RFP) packaged inside. Plasmids encoding the
PsV components, as well as human sera positive and negative for
HPV-16 antibodies, were the kind gift of Dr. John Schiller, National
Cancer Institute. HPV-16 PsV were generated by co-transfection of
HPV-16 genes encoding major L1 and minor L2 capsid proteins
and RFP as described (Buck et al., 2004, 2005; Roberts et al., 2007).
Cells were exposed to PsVs, and RFP expression indicating PsV
entry into epithelial cells was detected after 3 days.
HPV paracellular passage assays
For HPV paracellular penetration assays, polarized epithelial
cells were exposed to HPV-16 PsV-RFP at 1 ng per insert or explant
at the apical surface of cells. To detect paracellular passage of PsVs,
COS-1 cells were seeded on cover glass placed in the basolateral
chambers of inserts containing polarized epithelial cells. After 2 h
the inserts were removed. COS-1 cells were grown for 3 days with
basolateral media from polarized culture. The cells were then ﬁxed
and PsV infection was determined by detection of RFP-positive
cells using confocal microscopy. For quantitative analysis RFP-
positive COS-1 cells were counted and results are presented as a %
of RFP-positive cells. PsV penetration into tissue explants was
evaluated by detecting RFP signals after 3 days of incubation of
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tissue explants. Tissues were ﬁxed, sectioned and analyzed by
confocal microscopy.
Confocal immunoﬂuorescence
Immunostaining of tissue sections was performed as previously
described (Tugizov et al., 2007, 2012). Mouse anti-HIV-1 tat
(Immunodiagnostic Inc.) and goat anti-gp120 (Thermo Scientiﬁc)
were used for detection of HIV-1 proteins. To detect tight junction
proteins and immune cells, we used rabbit anti-ZO-1, anti-occlu-
din, and anti-claudin-1 (all from Zymed) and mouse anti-CD3,
anti-CD68 and anti-CD1a (all from BD Bioscience). Secondary
antibodies labeled with ﬂuorescein isothiocyanate (FITC), tetra-
methyl rhodamine isothiocyanate (TRITC), or cyanine 5 (Cy5) were
purchased from Jackson Immunoresearch. The speciﬁcity of each
antibody was conﬁrmed by negative staining with the correspond-
ing primary isotype control antibody. Cell nuclei were counter-
stained with TO-PRO-3 iodide (Molecular Probes) (blue). Cells and
tissue sections were analyzed using a Leica SP5 laser confocal
microscope.
For quantitative analysis of ZO-1-, occludin-, and claudin-1-
expressing epithelial cells, tissue sections were immunostained for
these proteins and we counted positive epithelial cells with a ring-
shaped staining pattern. The ring-shaped pattern of localization of
tight junction proteins indicates their association with intact tight
junctions. Cells with normal TJs were counted within the epithe-
lium in 10 microscopic ﬁelds (200 ) of each tissue section.
Results are represented as a percentage of cells with ring shaped
localization of TJ proteins.
For quantitative evaluation of HIV tat- and gp120-expressing
immune cells, sections were co-immunostained for viral proteins
with immune cell markers (CD68 for macrophages, CD1a for
Langerhans cells, CD3 for lymphocytes), and immune cells expres-
sing HIV proteins were counted. Cells were counted in 10 ran-
domly selected microscopic ﬁelds (200 ) per section in at least
three sections for each explant. Results were presented as the
average number of positive cells per mm2.
For quantitative analysis of HPV-16 PsV penetration into oral or
anal epithelia, sections of tissue explants exposed to PsVs were
immunostained with anti-ZO-1 or anti-occludin antibodies, and
the cells containing red signals were counted under various
experimental conditions. All cell quantiﬁcation was performed
blindly by two investigators (ST, RH).
Western blot and immunoprecipitation assays
Matching saliva and plasma samples (2 ml of each) from
HIV-infected (UCSF Options Study, Owotade et al., 2008) and
HIV-uninfected individuals were subjected to immunoprecipita-
tion using sheep anti-tat (Abcam) and mouse monoclonal anti-
gp120 antibodies (ID6) (NH AIDS Reagents). These samples (con-
centrated by approximately 20 times) were then analyzed by
immunoblotting with mouse anti-tat monoclonal (Immunodiag-
nostics Inc) and mouse anti-gp120 antibodies (ID6) (NIH AIDS
Research reagent program). As positive controls, gp120 and tat
were used for HIV-133-infected PBMC extract and recombinant tat
(HIV-1BAL strain) (Immunodiagnostics Inc), respectively. Bands
were visualized using ECL-detection system (GE Healthcare).
Detection of infectious HIV from anal tissue biopsies
Anal biopsies from consenting HIV-uninfected and HIV-infected
donors at the UCSF Anal Neoplasia Clinic and were weighed
and homogenized using sterile glass powder in 1 ml phosphate-
buffered saline (pH, 7.2). Tissue homogenates were centrifuged for
10 min at 2000 RPM, and supernatants were divided into two parts.
One part was used for detection of HIV-1 p24. The other part was
used for infection of PBMCs. HIV infection in PBMCs were examined
after 2 weeks by p24 ELISA.
Statistical analysis
To determine the disruption of epithelial TJs and intraepithelial
immune cells expressing HIV tat and gp120 proteins, data were
obtained from HIV-uninfected donors, and HIV-infected individuals
not on ART or treated with ART. The results were compared using
the Student's t-test; p values o0.05 were considered signiﬁcant.
Acknowledgments
We thank Dr. Teresa Darragh (UCSF) for histological evaluation of
tissues, Dr. Fred Fishman (UCSF) for providing the tissue biopsies, and
Ashok Chauhan (University of South Carolina) for providing GFP-tat
expressing plasmid pEGFP/HXB-2. This project was supported by
National Institute of Dental and Craniofacial Research (R21 DE021011),
California HIV/AIDS Research Program (ID10-SF-030), the UCSF Center
for AIDS Research (P30-AI027763), the Oral HIV/AIDS Research
Alliance (U01-AI-68636), the NCI AIDS Malignancy Consortium (U01
CA121947) and the Helen Diller Family Comprehensive Cancer Center
(P30 CA 82103-13).
References
Alcorn, J.F., Guala, A.S., van der Velden, J., McElhinney, B., Irvin, C.G., Davis, R.J.,
Janssen-Heininger, Y.M., 2008. Jun N-terminal kinase 1 regulates epithelial-to-
mesenchymal transition induced by TGF-beta1. J. Cell Sci. 121, 1036–1045.
Ali, A.S., Ali, S., El-Rayes, B.F., Philip, P.A., Sarkar, F.H., 2009. Exploitation of protein
kinase C: a useful target for cancer therapy. Cancer Treat. Rev. 35, 1–8.
Andras, I.E., Pu, H., Tian, J., Deli, M.A., Nath, A., Hennig, B., Toborek, M., 2005.
Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression
in brain endothelial cells. J. Cereb. Blood Flow Metab. 25, 1159–1170.
Bai, L., Zhang, Z., Zhang, H., Li, X., Yu, Q., Lin, H., Yang, W., 2008. HIV-1 Tat protein
alter the tight junction integrity and function of retinal pigment epithelium: an
in vitro study. BMC Infect. Dis. 8, 77.
Barillari, G., Sgadari, C., Fiorelli, V., Samaniego, F., Colombini, S., Manzari, V.,
Modesti, A., Nair, B.C., Cafaro, A., Sturzl, M., Ensoli, B., 1999a. The Tat protein
of human immunodeﬁciency virus type-1 promotes vascular cell growth and
locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by
mobilizing sequestered basic ﬁbroblast growth factor. Blood 94, 663–672.
Barillari, G., Sgadari, C., Palladino, C., Gendelman, R., Caputo, A., Morris, C.B., Nair, B.
C., Markham, P., Nel, A., Sturzl, M., Ensoli, B., 1999b. Inﬂammatory cytokines
synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's
sarcoma via induction of basic ﬁbroblast growth factor and the alpha v beta
3 integrin. J. Immunol. 163, 1929–1935.
Bozou, J.C., Rochet, N., Magnaldo, I., Vincent, J.P., Kitabgi, P., 1989. Neurotensin
stimulates inositol trisphosphate-mediated calcium mobilization but not pro-
tein kinase C activation in HT29 cells. Involvement of a G-protein. Biochem. J.
264, 871–878.
Buck, C.B., Day, P.M., Thompson, C.D., Lubkowski, J., Lu, W., Lowy, D.R., Schiller, J.T.,
2006. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad.
Sci. USA 103, 1516–1521.
Buck, C.B., Pastrana, D.V., Lowy, D.R., Schiller, J.T., 2004. Efﬁcient intracellular
assembly of papillomaviral vectors. J. Virol. 78, 751–757.
Buck, C.B., Thompson, C.D., Pang, Y.Y., Lowy, D.R., Schiller, J.T., 2005. Maturation of
papillomavirus capsids. J. Virol. 79, 2839–2846.
Cai, H., Smola, U., Wixler, V., Eisenmann-Tappe, I., Diaz-Meco, M.T., Moscat, J., Rapp, U.,
Cooper, G.M., 1997. Role of diacylglycerol-regulated protein kinase C isotypes
in growth factor activation of the Raf-1 protein kinase. Mol. Cell Biol. 17,
732–741.
Chou, L.L., Epstein, J., Cassol, S.A., West, D.M., He, W., Firth, J.D., 2000. Oral mucosal
Langerhans' cells as target, effector and vector in HIV infection. J. Oral. Pathol.
Med. 29, 394–402.
Clemetson, D.B., Moss, G.B., Willerford, D.M., Hensel, M., Emonyi, W., Holmes, K.K.,
Plummer, F., Ndinya-Achola, J., Roberts, P.L., Hillier, S., et al., 1993. Detection of
HIV DNA in cervical and vaginal secretions. Prevalence and correlates among
women in Nairobi, Kenya. JAMA: The Journal of the American Medical
Association 269, 2860–2864.
Crowe, S.M., Sonza, S., 2000. HIV-1 can be recovered from a variety of cells
including peripheral blood monocytes of patients receiving highly active
antiretroviral therapy: a further obstacle to eradication. J. Leukocyte Biol. 68,
345–350.
S.M. Tugizov et al. / Virology 446 (2013) 378–388386
Dayanithi, G., Yahi, N., Baghdiguian, S., Fantini, J., 1995. Intracellular calcium release
induced by human immunodeﬁciency virus type 1 (HIV-1) surface envelope
glycoprotein in human intestinal epithelial cells: a putative mechanism for
HIV-1 enteropathy. Cell Calcium 18, 9–18.
de Pokomandy, A., Rouleau, D., Ghattas, G., Vezina, S., Cote, P., Macleod, J., Allaire, G.,
Franco, E.L., Coutlee, F., 2009. Prevalence, clearance, and incidence of anal
human papillomavirus infection in HIV-infected men: the HIPVIRG cohort
study. J. Infect. Dis. 199, 965–973.
Fantini, J., Maresca, M., Hammache, D., Yahi, N., Delezay, O., 2000. Glycosphingo-
lipid (GSL) microdomains as attachment platforms for host pathogens and their
toxins on intestinal epithelial cells: activation of signal transduction pathways
and perturbations of intestinal absorption and secretion. Glycoconj. J. 17,
173–179.
Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M., Beltram, F., 2003.
Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins
visualized in real time. Mol. Ther.: J. Am. Soc. Gene Ther. 8, 284–294.
Fittipaldi, A., Ferrari, A., Zoppe, M., Arcangeli, C., Pellegrini, V., Beltram, F., Giacca, M.,
2003. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion
proteins. J. Biol. Chem. 278, 34141–34149.
Gonzalez-Mariscal, L., Tapia, R., Chamorro, D., 2008. Crosstalk of tight junction
components with signaling pathways. Biochim. Biophys. Acta 1778,
729–756.
Goto, Y., Yeh, C.K., Notkins, A.L., Prabhakar, B.S., 1991. Detection of proviral
sequences in saliva of patients infected with human immunodeﬁciency virus
type 1. AIDS Res. Hum. Retroviruses 7, 343–347.
Gulino, D., Delachanal, E., Concord, E., Genoux, Y., Morand, B., Valiron, M.O., Sulpice, E.,
Scaife, R., Alemany, M., Vernet, T., 1998. Alteration of endothelial cell monolayer
integrity triggers resynthesis of vascular endothelium cadherin. J. Biol. Chem. 273,
29786–29793.
Hatano, H., Delwart, E.L., Norris, P.J., Lee, T.H., Neilands, T.B., Kelley, C.F., Hunt, P.W.,
Hoh, R., Linnen, J.M., Martin, J.N., Busch, M.P., Deeks, S.G., 2010. Evidence of
persistent low-level viremia in long-term HAART-suppressed, HIV-infected
individuals. AIDS 24, 2535–2539.
Henning, T.R., Kissinger, P., Lacour, N., Meyaski-Schluter, M., Clark, R., Amedee, A.M.,
2010. Elevated cervical white blood cell inﬁltrate is associated with genital HIV
detection in a longitudinal cohort of antiretroviral therapy-adherent women. J.
Infect. Dis.202, 1543–1552.
Hessol, N.A., Holly, E.A., Eﬁrd, J.T., Minkoff, H., Schowalter, K., Darragh, T.M., Burk, R.D.,
Strickler, H.D., Greenblatt, R.M., Palefsky, J.M., 2009. Anal intraepithelial neoplasia
in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 23,
59–70.
Ishii, Y., 2013. Electron microscopic visualization of autophagosomes induced by
infection of human papillomavirus pseudovirions. Biochem. Biophys. Res.
Commun. 433, 385–389.
Jayakumar, P., Berger, I., Autschbach, F., Weinstein, M., Funke, B., Verdin, E.,
Goldsmith, M.A., Keppler, O.T., 2005. Tissue-resident macrophages are produc-
tively infected ex vivo by primary X4 isolates of human immunodeﬁciency
virus type 1. J. Virol. 79, 5220–5226.
Kakizawa, J., Ushijima, H., Oka, S., Ikeda, Y., Schroder, H.C., Muller, W.E., 1996.
Detection of human immunodeﬁciency virus-1 DNA, RNA and antibody, and
occult blood in inactivated saliva: availability of the ﬁlter paper disk method.
Acta Paediatr. Jpn. 38, 218–223.
Kang, M., Cu-Uvin, S., 2012. Association of HIV viral load and CD4 cell count with
human papillomavirus detection and clearance in HIV-infected women initiat-
ing highly active antiretroviral therapy. HIV Med. 13, 372–378.
Kanmogne, G.D., Primeaux, C., Grammas, P., 2005. HIV-1 gp120 proteins alter tight
junction protein expression and brain endothelial cell permeability: implica-
tions for the pathogenesis of HIV-associated dementia. J. Neuropathol. Exp.
Neurol. 64, 498–505.
Kanmogne, G.D., Schall, K., Leibhart, J., Knipe, B., Gendelman, H.E., Persidsky, Y.,
2007. HIV-1 gp120 compromises blood–brain barrier integrity and enhances
monocyte migration across blood–brain barrier: implication for viral neuro-
pathogenesis. J. Cereb. Blood Flow Metab. 27, 123–134.
Kapembwa, M.S., Fleming, S.C., Orr, M., Wells, C., Bland, M., Back, D., Grifﬁn, G.E.,
1996. Impaired absorption of zidovudine in patients with AIDS-related small
intestinal disease. AIDS 10, 1509–1514.
Kapembwa, M.S., Fleming, S.C., Sewankambo, N., Serwadda, D., Lucas, S., Moody, A.,
Grifﬁn, G.E., 1991. Altered small-intestinal permeability associated with diar-
rhoea in human-immunodeﬁciency-virus-infected Caucasian and African sub-
jects. Clin. Sci. (Lond.) 81, 327–334.
Kaplan, I.M., Wadia, J.S., Dowdy, S.F., 2005. Cationic TAT peptide transduction
domain enters cells by macropinocytosis. J. Contr. Release: Ofﬁcial Journal of
the Controlled Release Society 102, 247–253.
Kawakami, Y., Nishimoto, H., Kitaura, J., Maeda-Yamamoto, M., Kato, R.M., Littman, D.R.,
Leitges, M., Rawlings, D.J., Kawakami, T., 2004. Protein kinase C betaII regulates Akt
phosphorylation on Ser-473 in a cell type- and stimulus-speciﬁc fashion. J. Biol.
Chem. 279, 47720–47725.
Kevil, C.G., Oshima, T., Alexander, B., Coe, L.L., Alexander, J.S., 2000. H(2)O(2)-
mediated permeability: role of MAPK and occludin. Am. J. Physiol. Cell Physiol.
279, C21–C30.
Kevil, C.G., Oshima, T., Alexander, J.S., 2001. The role of p38 MAP kinase in hydrogen
peroxide mediated endothelial solute permeability. Endothelium 8, 107–116.
Liuzzi, G., Chirianni, A., Clementi, M., Bagnarelli, P., Valenza, A., Cataldo, P.T.,
Piazza, M., 1996. Analysis of HIV-1 load in blood, semen and saliva: evidence
for different viral compartments in a cross-sectional and longitudinal study.
AIDS 10, F51–F56.
Lopez-Bergami, P., Habelhah, H., Bhoumik, A., Zhang, W., Wang, L.H., Ronai, Z., 2005.
RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol. Cell 19,
309–320.
Maingat, F., Halloran, B., Acharjee, S., van Marle, G., Church, D., Gill, M.J., Uwiera, R.R.,
Cohen, E.A., Meddings, J., Madsen, K., Power, C., 2011. Inﬂammation and epithelial
cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress.
FASEB J.: Ofﬁcial Publication of the Federation of American Societies for Experi-
mental Biology 25, 2211–2220.
Mann, D.A., Frankel, A.D., 1991. Endocytosis and targeting of exogenous HIV-1 Tat
protein. EMBO J. 10, 1733–1739.
Marshall, C.J., 1996. Cell signalling. Raf gets it together. Nature 383, 127–128.
Maticic, M., Poljak, M., Kramar, B., Tomazic, J., Vidmar, L., Zakotnik, B., Skaleric, U.,
2000. Proviral HIV-1 DNA in gingival crevicular ﬂuid of HIV-1-infected patients
in various stages of HIV disease. J. Dent. Res. 79, 1496–1501.
Mediouni, S., Darque, A., Baillat, G., Ravaux, I., Dhiver, C., Tissot-Dupont, H.,
Mokhtari, M., Moreau, H., Tamalet, C., Brunet, C., Paul, P., Dignat-George, F.,
Stein, A., Brouqui, P., Spector, S.A., Campbell, G.R., Loret, E.P., 2012. Antiretroviral
therapy does not block the secretion of the human immunodeﬁciency virus tat
protein. Infect. Disord. Drug Targets 12, 81–86.
Montagnier, L., Clavel, F., Krust, B., Chamaret, S., Rey, F., Barre-Sinoussi, F.,
Chermann, J.C., 1985. Identiﬁcation and antigenicity of the major envelope
glycoprotein of lymphadenopathy-associated virus. Virology 144, 283–289.
Nagahara, H., Vocero-Akbani, A.M., Snyder, E.L., Ho, A., Latham, D.G., Lissy, N.A.,
Becker-Hapak, M., Ezhevsky, S.A., Dowdy, S.F., 1998. Transduction of full-length
TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.
Nat. Med. 4, 1449–1452.
Nakamuta, S., Endo, H., Higashi, Y., Kousaka, A., Yamada, H., Yano, M., Kido, H., 2008.
Human immunodeﬁciency virus type 1 gp120-mediated disruption of tight
junction proteins by induction of proteasome-mediated degradation of zonula
occludens-1 and -2 in human brain microvascular endothelial cells. J. Neuro-
virol. 14, 186–195.
Nazli, A., Chan, O., Dobson-Belaire, W.N., Ouellet, M., Tremblay, M.J., Gray-Owen, S.D.,
Arsenault, A.L., Kaushic, C., 2010. Exposure to HIV-1 directly impairs mucosal
epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6,
e1000852, http://dx.doi.org/10.1371/journal.ppat.1000852.
Nuovo, G.J., Forde, A., MacConnell, P., Fahrenwald, R., 1993. In situ detection of PCR-
ampliﬁed HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical
tissues. Am. J. Pathol. 143, 40–48.
Obinna, F.C., Cook, G., Beale, T., Dave, S., Cunningham, D., Fleming, S.C., Claydon, E.,
Harris, J.W., Kapembwa, M.S., 1995. Comparative assessment of small intestinal
and colonic permeability in HIV-infected homosexual men. AIDS 9, 1009–1016.
Oh, S.K., Cruikshank, W.W., Raina, J., Blanchard, G.C., Adler, W.H., Walker, J.,
Kornfeld, H., 1992. Identiﬁcation of HIV-1 envelope glycoprotein in the serum
of AIDS and ARC patients. J. Acquir. Immune Deﬁc. Syndr. 5, 251–256.
Owotade, F.J., Shiboski, C.H., Poole, L., Ramstead, C.A., Malvin, K., Hecht, F.M.,
Greenspan, J.S., 2008. Prevalence of oral disease among adults with primary
HIV infection. Oral Dis.14, 497–499.
Palefsky, J., 2006. Biology of HPV in HIV infection. Adv. Dent. Res. 19, 99–105.
Palefsky, J.M., 2009. Anal cancer prevention in HIV-positive men and women. Curr.
Opin. Oncol. 21, 433–438.
Palefsky, J.M., 2012. Antiretroviral therapy and anal cancer: the good, the bad, and
the unknown. Sex. Transm. Dis.39, 501–503.
Palefsky, J.M., Holly, E.A., Eﬁrdc, J.T., Da Costa, M., Jay, N., Berry, J.M., Darragh, T.M.,
2005. Anal intraepithelial neoplasia in the highly active antiretroviral therapy
era among HIV-positive men who have sex with men. AIDS 19, 1407–1414.
Palefsky, J.M., Holly, E.A., Ralston, M.L., Jay, N., 1998. Prevalence and risk factors for
human papillomavirus infection of the anal canal in human immunodeﬁciency
virus (HIV)-positive and HIV-negative homosexual men. J. Infect. Dis.177,
361–367.
Poggi, A., Zocchi, M.R., 2006. HIV-1 Tat triggers TGF-beta production and NK cell
apoptosis that is prevented by pertussis toxin B. Clin. Dev. Immunol. 13,
369–372.
Preiss, S., Namgaladze, D., Brune, B., 2007. Critical role for classical PKC in activating
Akt by phospholipase A2-modiﬁed LDL in monocytic cells. Cardiovasc. Res. 73,
833–840.
Pu, H., Tian, J., Andras, I.E., Hayashi, K., Flora, G., Hennig, B., Toborek, M., 2005. HIV-1
Tat protein-induced alterations of ZO-1 expression are mediated by redox-
regulated ERK 1/2 activation. J. Cereb. Blood Flow Metab. 25, 1325–1335.
Qureshi, M.N., Barr, C.E., Hewlitt, I., Boorstein, R., Kong, F., Bagasra, O., Bobroski, L.E.,
Joshi, B., 1997. Detection of HIV in oral mucosal cells. Oral Dis. 3 (Suppl 1),
S73–S78.
Qureshi, M.N., Barr, C.E., Seshamma, T., Reidy, J., Pomerantz, R.J., Bagasra, O., 1995.
Infection of oral mucosal cells by human immunodeﬁciency virus type 1 in
seropositive persons. J. Infect. Dis. 171, 190–193.
Roberts, J.N., Buck, C.B., Thompson, C.D., Kines, R., Bernardo, M., Choyke, P.L.,
Lowy, D.R., Schiller, J.T., 2007. Genital transmission of HPV in a mouse model is
potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13,
857–861.
Rodriguez-Inigo, E., Jimenez, E., Bartolome, J., Ortiz-Movilla, N., Bartolome Villar, B.,
Jose Arrieta, J., Manzarbeitia, F., Carreno, V., 2005. Detection of human
immunodeﬁciency virus type 1 RNA by in situ hybridization in oral mucosa
epithelial cells from anti-HIV-1 positive patients. J. Med. Virol. 77, 17–22.
Rychert, J., Strick, D., Bazner, S., Robinson, J., Rosenberg, E., 2010. Detection of HIV
gp120 in plasma during early HIV infection is associated with increased
proinﬂammatory and immunoregulatory cytokines. AIDS Res. Human Retro-
viruses 26, 1139–1145.
S.M. Tugizov et al. / Virology 446 (2013) 378–388 387
Sankaran, S., George, M.D., Reay, E., Guadalupe, M., Flamm, J., Prindiville, T.,
Dandekar, S., 2008. Rapid onset of intestinal epithelial barrier dysfunction in
primary human immunodeﬁciency virus infection is driven by an imbalance
between immune response and mucosal repair and regeneration. J. Virol. 82,
538–545.
Santosuosso, M., Righi, E., Lindstrom, V., Leblanc, P.R., Poznansky, M.C., 2009. HIV-1
envelope protein gp120 is present at high concentrations in secondary
lymphoid organs of individuals with chronic HIV-1 infection. J. Infect. Dis.
200, 1050–1053.
Schupbach, J., Gunthard, H., Joos, B., Fischer, M., Boni, J., Tomasik, Z., Yerly, S., Perrin,
L., Battegay, M., Furrer, H., Vernazza, P., Bernasconi, E., Hirschel, B., 2005. HIV-1
p24 may persist during long-term highly active antiretroviral therapy, increases
little during short treatment breaks, and its rebound after treatment stop
correlates with CD4(þ) T cell loss. J. Acquir. Immune Deﬁc. Syndr. 40, 250–256.
Shen, L., Turner, J.R., 2005. Actin depolymerization disrupts tight junctions via
caveolae-mediated endocytosis. Mol. Biol. Cell16, 3919–3936.
Shin, K., Fogg, V.C., Margolis, B., 2006. Tight junctions and cell polarity. Annu. Rev.
Cell Dev. Biol.22, 207–235.
Shintani, Y., Hollingsworth, M.A., Wheelock, M.J., Johnson, K.R., 2006. Collagen I
promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal
kinase 1 and up-regulating N-cadherin expression. Cancer Res. 66, 11745–11753.
Song, L., Ge, S., Pachter, J.S., 2007. Caveolin-1 regulates expression of junction-
associated proteins in brain microvascular endothelial cells. Blood 109,
1515–1523.
Sonza, S., Mutimer, H.P., Oelrichs, R., Jardine, D., Harvey, K., Dunne, A., Purcell, D.F.,
Birch, C., Crowe, S.M., 2001. Monocytes harbour replication-competent, non-
latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15, 17–22.
Toschi, E., Bacigalupo, I., Strippoli, R., Chiozzini, C., Cereseto, A., Falchi, M., Nappi, F.,
Sgadari, C., Barillari, G., Mainiero, F., Ensoli, B., 2006. HIV-1 Tat regulates
endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling
pathway. Mol. Biol. Cell 17, 1985–1994.
Tugizov, S., Herrera, R., Veluppillai, P., Greenspan, J., Greenspan, D., Palefsky, J.M.,
2007. Epstein–Barr virus (EBV)-infected monocytes facilitate dissemination of
ebv within the oral mucosal epithelium. J. Virol. 81, 5484–5496.
Tugizov, S.M., Berline, J.W., Palefsky, J.M., 2003. Epstein–Barr virus infection of
polarized tongue and nasopharyngeal epithelial cells. Nat. Med. 9, 307–314.
Tugizov, S.M., Herrera, R., Veluppillai, P., Greenspan, D., Soros, V., Greene, W.C.,
Levy, J.A., Palefsky, J.M., 2011. HIV is inactivated after transepithelial migration
via adult oral epithelial cells but not fetal epithelial cells. Virology 409,
211–222.
Tugizov, S.M., Herrera, R., Veluppillai, P., Greenspan, D., Soros, V., Greene, W.C.,
Levy, J.A., Palefsky, J.M., 2012. Differential transmission of HIV traversing fetal
oral/intestinal epithelia and adult oral epithelia. J. Virol. 86, 2556–2570.
Umeda, K., Ikenouchi, J., Katahira-Tayama, S., Furuse, K., Sasaki, H., Nakayama, M.,
Matsui, T., Tsukita, S., Furuse, M., 2006. ZO-1 and ZO-2 independently
determine where claudins are polymerized in tight-junction strand formation.
Cell 126, 741–754.
Wadia, J.S., Stan, R.V., Dowdy, S.F., 2004. Transducible TAT-HA fusogenic peptide
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat.
Med. 10, 310–315.
Wang, Y., Zhang, J., Yi, X.J., Yu, F.S., 2004. Activation of ERK1/2 MAP kinase pathway
induces tight junction disruption in human corneal epithelial cells. Exp. Eye
Res. 78, 125–136.
Westendorp, M.O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H.,
Debatin, K.M., Krammer, P.H., 1995. Sensitization of T cells to CD95-mediated
apoptosis by HIV-1 Tat and gp120. Nature 375, 497–500.
Xiao, H., Neuveut, C., Tiffany, H.L., Benkirane, M., Rich, E.A., Murphy, P.M., Jeang, K.T.,
2000. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of
coreceptor use by HIV-1. Proc. Natl. Acad. Sci. USA 97, 11466–11471.
Yang, B., Akhter, S., Chaudhuri, A., Kanmogne, G.D., 2009. HIV-1 gp120 induces
cytokine expression, leukocyte adhesion, and transmigration across the blood–
brain barrier: modulatory effects of STAT1 signaling. Microvasc. Res. 77,
212–219.
Zhang, J., Crumpacker, C.S., 2001. Human immunodeﬁciency virus type 1 RNA in
peripheral blood mononuclear cells of patients receiving prolonged highly
active antiretroviral therapy. J. Infect. Dis.184, 1341–1344.
Zhong, Y., Smart, E.J., Weksler, B., Couraud, P.O., Hennig, B., Toborek, M., 2008.
Caveolin-1 regulates human immunodeﬁciency virus-1 Tat-induced alterations
of tight junction protein expression via modulation of the Ras signaling. J.
Neurosci. 28, 7788–7796.
Zhou, H., Das, S., Murthy, K.S., 2003. Erk1/2- and p38 MAP kinase-dependent
phosphorylation and activation of cPLA2 by m3 and m2 receptors. Am. J.
Physiol. Gastrointest. Liver Physiol. 284, G472–G480.
Zuckerman, R.A., Whittington, W.L., Celum, C.L., Collis, T., Lucchetti, A., Sanchez, J.L.,
Hughes, J.P., Coombs, R.W., 2003. Factors associated with oropharyngeal human
immunodeﬁciency virus shedding. J. Infect. Dis. 188, 142–145.
S.M. Tugizov et al. / Virology 446 (2013) 378–388388
